Symbols

CABA

Cabaletta Bio·NASDAQ

--(--)

CABA Profile

Cabaletta Bio, Inc.

A clinical-stage biotech company focused on targeted cell therapies for autoimmune diseases

Industry

Biological Technology

Established Date

Listing Date

10/25/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

154

Fiscal Year Ends

12-31

Website

www.cabalettabio.com

Security Type

Common stock

Office address

2929 Arch Street Suite 600 Philadelphia PA 19104

Business

Introduction

Cabaletta Bio, Inc., was incorporated under the laws of the State of Delaware in April 2017. The company is a clinical-stage biotechnology company focused on discovering and developing engineered T-cell therapies that have the potential to provide a deep and durable, perhaps therapeutic, treatment for patients with autoimmune diseases.